Prostate-specific membrane antigen (PSMA) as a theranostic agent is driving changes in prostate cancer including both clinical development of new drugs and clinical care. The sensitivity of PSMA ...
Buoyed by data from a trial of its T-cell engager (TCE) therapy in prostate cancer that almost tripled its share price, Janux Therapeutics has moved quickly to file a stock offering that could add ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback